Baxter International (BAX)

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) between February 23, 2022 and July 30, 2025, inclusive.

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) --

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), have until December 15, 2025 to seek appointment as lead plaintiff of the Baxter class action lawsuit. Captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., No. 25-cv-12672 (N.D. Ill.), the Baxter class action lawsuit charges Baxter and certain of Baxter’s top current and former executives with violations of the Securities Exchange Act of 1934.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options

SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025. Baxter is a global company that develops, manufactures, and markets medical products used in hospitals and other healthcare facilities.

The DJS Law Group reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

PHILADELPHIA, Oct. 20, 2025 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE:BAX) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”). Baxter develops, manufactures, and markets medical products.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Labaton Keller Sucharow LLP (“Labaton”) has filed a securities class action lawsuit (the “Action”) on behalf of its client the Electrical Workers Pension Fund, Local 103, I.B.E.W. (“Local 103”) against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) and certain of its executives (collectively, “Defendants”). The Action, which is captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., No. 25-cv-12672 (N.D. Ill.), asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons and entities that purchased or otherwise acquired Baxter common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).

Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its third-quarter 2025 financial results on Thursday, October 30, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156235 to pre-register for the call and receive the call information.

Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has been awarded a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC) in the categories of IV Solutions, Nutrition Solutions and Premix Drugs. Baxter is the first manufacturer to earn this distinction across these categories, underscoring Baxter’s commitment to building a stronger, more reliable supply chain.

Baxter International Inc. (NYSE:BAX), a leading global medtech company, today launched the Welch Allyn Connex 360 Vital Signs Monitor, its next generation patient monitoring device. As the latest innovation in Baxter’s connected monitoring portfolio, Connex 360 offers an advanced connectivity and security platform, customizable configurations based on a hospital’s clinical routines, and upgrade capabilities that set the stage for future functionality and enhancements. With automated clinical documentation, Connex 360 is designed to simplify the clinician experience and allow more time to focus on patients.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2025.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on October 1, 2025, to stockholders of record as of August 29, 2025. The indicated annual dividend rate is $0.68 per share of common stock.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its 2024 Corporate Responsibility Report. The annual report demonstrates Baxter's commitment to transparent reporting and provides updates on the company’s 2030 Corporate Responsibility Commitment and Goals,1 which strive to create a more sustainable and responsible business model.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025.